Telix Pharmaceuticals Limited (TLX)
Automate Your Wheel Strategy on TLX
With Tiblio's Option Bot, you can configure your own wheel strategy including TLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLX
- Rev/Share 3.5211
- Book/Share 1.2513
- PB 11.6534
- Debt/Equity 0.9913
- CurrentRatio 1.333
- ROIC 0.063
- MktCap 4935756736.7412
- FreeCF/Share 0.0176
- PFCF 833.6764
- PE 141.4713
- Debt/Assets 0.3515
- DivYield 0
- ROE 0.0702
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TLX | Citigroup | -- | Buy | -- | $22 | Sept. 18, 2025 |
| Downgrade | TLX | JP Morgan | Overweight | Neutral | -- | -- | Aug. 28, 2025 |
| Initiation | TLX | H.C. Wainwright | -- | Buy | -- | $23 | July 3, 2025 |
| Initiation | TLX | Wedbush | -- | Outperform | -- | $22 | June 5, 2025 |
News
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter – Hagens Berman
Published: November 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter. National shareholders rights firm Hagens Berman is actively investigating the alleged legal claims and urges Telix investors who suffered substantial losses to submit your losses now.
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers.
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 14, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or "the Company") (NASDAQ: TLX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Telix securities between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period").
Read More
TLX DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLX
Published: November 14, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" or the …
Read More
ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX
Published: November 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2026 in the securities class action first filed by the Firm.
Read More
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
Published: November 12, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period").
Read More
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
Published: November 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter.
Read More
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing
Published: November 12, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf Telix Pharmaceuticals (TLX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: November 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (“Telix”) (NASDAQ: TLX). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Telix's business, operations, and prospects, including allegations that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materials overstated the quality of Telix's supply chain and partners; and (3) as a result, defendants statements about Telix's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis …
Read More
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Published: November 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period").
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers.
Read More
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
Published: November 11, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period").
Read More
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.
Read More
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: October 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.
Read More
Telix Pharmaceuticals Limited Investigated by the Portnoy Law Firm
Published: October 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Telix Pharmaceuticals Limited, ("Telex" or the "Company") (NASDAQ: TLX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Read More
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: October 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.
Read More
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
Published: October 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.
Read More
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.
Read More
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: September 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.
Read More
CMS Grants Transitional Pass-Through Status for Gozellix
Published: September 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET1 imaging agent for prostate cancer.
Read More
Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- On August 28, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares fall about 16% after the company said the FDA sought more data on its drug to detect a form of kidney cancer.
Read More
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
Published: September 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd.
Read More
Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable
Published: August 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Despite recent FDA rejections and a ~50% share price drop, I remain bullish on TLX, viewing setbacks as surmountable. Strong revenue performance and cash flow stability provide TLX with ample runway to address regulatory and developmental challenges. FDA complete response letters for Pixclara and Zircaix are based on fixable issues, not dead ends, supporting eventual approval prospects.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
Published: August 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Telix Pharmaceuticals Limited (TLX) Q2 2025 Earnings Call Transcript
Published: August 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Telix Pharmaceuticals Limited (NASDAQ:TLX ) Q2 2025 Earnings Conference Call August 20, 2025 7:30 PM ET Company Participants Christian P. Behrenbruch - Co-Founder, MD, Group CEO & Executive Director Darren Smith - Group Chief Financial Officer Kevin Richardson - Chief Executive Officer of Telix Precision Medicine Kyahn Williamson - Senior Vice President of Corporate Communications & Investor Relations Richard Valeix - Chief Executive Officer of Telix Therapeutics Conference Call Participants David A.
Read More
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX
Published: August 21, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public. So What: If you purchased Telix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen.
Read More
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC. Telix's revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Telix may have misled investors about certain of its drug candidates and urges Telix investors who suffered substantial losses to submit your losses now.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
About Telix Pharmaceuticals Limited (TLX)
- IPO Date 2024-11-14
- Website https://telixpharma.com
- Industry Biotechnology
- CEO Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, MBA
- Employees None